AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

Press/Media: Press / Media

PeriodApr 15 2016

Media coverage

1

Media coverage

  • TitleAbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs
    Media name/outletNews-Medical.Net
    CountryAustralia
    Date4/15/16
    PersonsFred Poordad